SCHEMBL2532738

SCHEMBL2532738

Cc1ccc2nc(-c3ccccc3)nc(N3CCOCC3)c2n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 9/20 0.59
GAA P10253 1/20 0.59
HTT P42858 3/20 0.55
LMNA P02545 2/20 0.55
PIK3CD O00329 6/20 0.54
PIK3CG P48736 5/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
ALDH1A1 P00352 4/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
CYP1A2 P05177 3/20 0.51
USP2 O75604 2/20 0.51
CYP3A4 P08684 2/20 0.51
ALOX15 P16050 2/20 0.51
TSHR P16473 2/20 0.51
CYP2C19 P33261 2/20 0.51
CLK4 Q9HAZ1 2/20 0.51
KDM4E B2RXH2 1/20 0.51
TRPM8 Q7Z2W7 1/20 0.51
CYP2C9 P11712 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2531267 0.79 PIK3CA (0.54) PIK3CAGAAHTTLMNAPIK3CD
SCHEMBL2531939 0.79 SMN1; SMN2 (0.50) PIK3CAGAAMEN1KMT2AALDH1A1
SCHEMBL3748887 0.78 HTT (0.84) PIK3CAGAAHTTLMNAMEN1
SCHEMBL11848248 0.75 PIK3CA (0.54) PIK3CAGAAHTTPIK3CDPIK3CG
SCHEMBL16919667 0.75 PIK3CA (0.55) PIK3CAGAAHTTLMNAPIK3CD
SCHEMBL1373862 0.75 GAA (0.63) PIK3CAGAAHTTLMNAMEN1
SCHEMBL11862881 0.74 ALDH1A1 (0.48) PIK3CAGAAPIK3CDPIK3CGMEN1
SCHEMBL258434 0.74 PIK3CA (1.00) PIK3CAGAAHTTLMNAPIK3CD
SCHEMBL258630 0.74 PIK3CA (0.69) PIK3CAGAAHTTLMNAMEN1
SCHEMBL16919637 0.74 PIK3CA (0.57) PIK3CAGAAHTTLMNAPIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO SA (CH) 2011-10-20 US disclosed
WO-2010037765-A2 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES MERCK SERONO S.A. (CH) 2010-04-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257170-A1 4-MORPHOLINO-PYRIDO[3,2-D]PYRIMIDINES PIK3CA, PIK3CD, PIK3CG PIK3CA 1/4885GAA 3592/4885HTT 3933/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.